Third Quarter 2019 Results

Bayer AG News Conference Call

Bayer: Encouraging business performance across all divisions – agreements signed to divest Currenta and Animal Health


  • Group sales increase by 5.4 percent (Fx & portfolio adj.) to 9.830 billion euros
  • EBITDA before special items advances by 7.5 percent to 2.291 billion euros
  • Crop Science reports higher sales and substantial earnings growth
  • Pharmaceuticals increases sales – earnings decline due to one-time income in prior year
  • Consumer Health posts growth in sales (Fx & portfolio adj.) and earnings
  • Net income declines by 63.9 percent to 1.036 billion euros – substantial divestment gain included in prior year
  • Core earnings per share up by 6.4 percent to 1.16 euros
  • Group outlook confirmed and aligned to continuing operations





Quarterly Statement Q3 2019

Press kit

Audio Recording: MP3 for download (10.75 MB, 61:00 min.) (dubbed into English)

Audio Recording: Webcast with slides



Follow us:


Twitter    Twitter

             You will find the key statements on » Twitter